Finding a way through the cost and benefit maze.
作者信息
Szczepura A
出版信息
BMJ. 1994 Nov 19;309(6965):1314-5. doi: 10.1136/bmj.309.6965.1314.
Abstract
摘要
相似文献
1
Finding a way through the cost and benefit maze.找到一条穿越成本与收益迷宫的路。
BMJ. 1994 Nov 19;309(6965):1314-5. doi: 10.1136/bmj.309.6965.1314.
2
Study assigns dollar value to alteplase-streptokinase debate.研究为阿替普酶与链激酶的争论赋予了货币价值。
Am J Health Syst Pharm. 1995 Aug 1;52(15):1600. doi: 10.1093/ajhp/52.15.1600.
3
Is alteplase (t-PA) more cost-effective than streptokinase?阿替普酶（组织型纤溶酶原激活剂）比链激酶更具成本效益吗？
Pharmacoeconomics. 1992 Nov;2(5):427-8. doi: 10.2165/00019053-199202050-00011.
4
Cost effectiveness of thrombolytic therapy with tissue plasminogen activator as compared with streptokinase for acute myocardial infarction.与链激酶相比，组织型纤溶酶原激活剂溶栓治疗急性心肌梗死的成本效益。
N Engl J Med. 1995 May 25;332(21):1418-24. doi: 10.1056/NEJM199505253322106.
5
Cost-effective care.具有成本效益的护理。
Health Serv J. 1995 Dec 14;105(5483):suppl 5 p..
6
The evidence base for the cost effectiveness of cardiac rehabilitation.心脏康复成本效益的证据基础。
Heart. 1997 Jul;78(1):5-6. doi: 10.1136/hrt.78.1.5.
7
Interpreting results from thrombolytic megatrials: distinguishing fact from fiction.解读溶栓大型试验的结果：区分事实与虚构。
Can J Cardiol. 1996 Jan;12(1):89-92.
8
Cost implications of cardiac rehabilitation in older patients.老年患者心脏康复的成本影响
Coron Artery Dis. 1999;10(1):53-6. doi: 10.1097/00019501-199901000-00010.
9
Tissue plasminogen activator was cost-effective compared to streptokinase in only selected patients with acute myocardial infarction.在仅部分急性心肌梗死患者中，与链激酶相比，组织型纤溶酶原激活剂具有成本效益。
J Clin Epidemiol. 2004 Aug;57(8):843-52. doi: 10.1016/j.jclinepi.2004.01.008.
引用本文的文献
1
Clinical guidelines in 1994.1994年的临床指南。
BMJ. 1994 Dec 3;309(6967):1457-8. doi: 10.1136/bmj.309.6967.1457.
2
Economic evaluation in rheumatology: a necessity for clinical studies.风湿病学中的经济评估：临床研究的必要性。
Ann Rheum Dis. 1995 Nov;54(11):863-4. doi: 10.1136/ard.54.11.863.
本文引用的文献
1
Use of claims data to monitor patients over time: acute myocardial infarction as a case study.
Ann N Y Acad Sci. 1993 Dec 31;703:63-72; discussion 72-3. doi: 10.1111/j.1749-6632.1993.tb26336.x.
2
Purchasing clinically effective care.购买临床有效护理。
BMJ. 1994 Oct 1;309(6958):823-4. doi: 10.1136/bmj.309.6958.823.
3
Cardiology--I: Treatment of myocardial infarction, unstable angina, and angina pectoris.心脏病学——I：心肌梗死、不稳定型心绞痛和心绞痛的治疗。
BMJ. 1994 Nov 19;309(6965):1343-50. doi: 10.1136/bmj.309.6965.1343.
4
Cost benefit analysis of early thrombolytic treatment with intracoronary streptokinase. Twelve month follow up report of the randomised multicentre trial conducted by the Interuniversity Cardiology Institute of The Netherlands.冠状动脉内链激酶早期溶栓治疗的成本效益分析。荷兰大学间心脏病学研究所进行的随机多中心试验的12个月随访报告。
Br Heart J. 1988 May;59(5):527-34. doi: 10.1136/hrt.59.5.527.
5
Cost-utility analysis of thrombolytic therapy.溶栓治疗的成本效用分析。
Eur Heart J. 1991 Jun;12(6):694-9. doi: 10.1093/eurheartj/12.6.694.
Zotero 插件